Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$2.93
+1.0%
$3.33
$1.72
$3.84
$27.53M1.4925,978 shs2,465 shs
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
$18.14
-0.4%
$18.00
$16.36
$18.60
N/AN/A30,540 shs21,134 shs
NVH
Novoheart
C$0.53
+1.9%
C$0.53
C$0.26
C$0.72
C$99.98MN/A33,593 shs23,066 shs
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
$11.21
+0.1%
$11.11
$10.52
$11.92
$242.15M-0.0127,212 shs449,602 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-0.39%-4.30%-13.87%+14.84%+8.37%
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
-0.44%+1.28%+0.11%+3.30%-2.16%
NVH
Novoheart
0.00%0.00%0.00%0.00%0.00%
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
+0.09%+0.22%+0.90%+1.72%+6.56%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
1.927 of 5 stars
3.53.00.00.00.60.81.3
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
N/AN/AN/AN/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/AN/AN/AN/A
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.00104.88% Upside
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
N/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/A
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
N/AN/AN/AN/A

Current Analyst Ratings

Latest ETX, OBD, RENE, NVH, and ACST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/7/2024
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
$5.32MN/AN/AN/AN/AN/A
NVH
Novoheart
C$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
N/AN/A$0.40 per share28.14($0.64) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
N/AN/A0.00N/AN/AN/AN/AN/A
NVH
Novoheart
N/A-C$0.04N/AN/AN/AN/AN/AN/A
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
$11.44MN/A0.00N/AN/A-65.59%5.02%N/A

Latest ETX, OBD, RENE, NVH, and ACST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/12/202412/31/2023
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$0.23-$0.21+$0.02-$0.21N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
$0.784.30%N/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/A
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
N/AN/AN/AN/AN/A

Latest ETX, OBD, RENE, NVH, and ACST Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/1/2024
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
Monthly$0.07805.28%4/22/20244/23/20244/30/2024
3/1/2024
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
monthly$0.07825.2%3/20/20243/21/20243/28/2024
2/1/2024
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
monthly$0.07825.3%2/21/20242/22/20242/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
N/AN/AN/A
NVH
Novoheart
27.62
6.13
6.05
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
N/A
0.22
0.22

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
Eaton Vance Municipal Income 2028 Term Trust stock logo
ETX
Eaton Vance Municipal Income 2028 Term Trust
N/AN/AN/ANot Optionable
NVH
Novoheart
N/A188.64 millionN/ANot Optionable
Cartesian Growth Co. II stock logo
RENE
Cartesian Growth Co. II
N/A21.62 million17.30 millionNot Optionable

ETX, OBD, RENE, NVH, and ACST Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Eaton Vance Municipal Income 2028 Term Trust logo

Eaton Vance Municipal Income 2028 Term Trust

NYSE:ETX
Eaton Vance Municipal Income 2028 Term Trust is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in the fixed income markets. The fund invest in stocks of companies operating across the diversified sectors. It was previously known as Eaton Vance Municipal Income Term Trust. Eaton Vance Municipal Income 2028 Term Trust was formed on March 28, 2013 and is domiciled in the United States.

Novoheart

CVE:NVH
Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.
Cartesian Growth Co. II logo

Cartesian Growth Co. II

NASDAQ:RENE
Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York.